SEATTLE, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced updates featuring the Company’s alpha-particle radiopharmaceuticals at the World Molecular Imaging Congress (WMIC) 2024, held on September 9-13, 2024, in Québec, Canada.
“We are pleased with the additional data that support the continued development of our alpha-particle therapies,” said Thijs Spoor, Perspective Therapeutics' CEO. “The data demonstrate the need for customized chelators to maximize stability and targeted delivery of potent alpha-particles. Additionally, our novel FAP-targeting candidate, PSV-359, continues to show favorable safety and strong efficacy profiles in preclinical studies.”
Presentation One: Preclinical evaluation of [203/212Pb]Pb-PSV-359 for imaging and alpha-particle therapy of cancers expressing fibroblast activation protein (FAP)**
Summary: The objective of this study is to evaluate [203/212Pb]Pb-radiolabeled PSV-359 in vitro and in vivo. PSV359 comprises a novel cyclic peptide targeting human FAP (hFAP), and a molecular linker to a lead-specific chelator. The researcher found that in vitro, [203/212Pb]Pb-PSV-359 demonstrated superior FAP binding affinity and specificity, and that [203Pb]Pb-PSV-359 showed strong tumor uptake and clearance from the blood via the renal system. In the study, [212Pb]Pb-PSV-359 also showed strong anti-tumor effects in xenograft models in which FAP was either on cancer cells or in stromal tissues.
Presenter: Brianna S. Cagle, PhD, Research Scientist, Perspective Therapeutics
Presentation Two: Customizing chelators for targeted radionuclide therapy: Insights from computational modeling
Summary: Researchers demonstrated the use and importance of computational methods to guide customization of chelators. They found that appropriate matching of the chelator to the specific radionuclide to ensure stability and targeted delivery is integral to the success of targeted radionuclide therapy (TRT). With the support of computational modeling, the investigators used multiple chelators that are commonly used in TRT, along with alpha emitters, beta emitters, and imaging tracers to determine compatibility between chelators and radionuclides. The study confirmed that modified chelators demonstrated superior performance when compared to conventional chelators.
Presenter: Jeongyun Kim, Doctoral Student, Seoul National University
**Presentation selected to be featured in the highlights of the closing lecture.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides, which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include express or implied statements concerning, among other things, the Company’s ability to pioneer advanced treatment applications for cancers throughout the body; expectations regarding the timing and advancement of the Company’s clinical and preclinical programs; the potential for customized chelators to maximize stability and targeted delivery of alpha-particles; the FAP binding affinity and specificity of [203/212Pb]Pb-PSV-359; the potential safety and efficacy of the Company’s FAP-targeting candidate, PSV-359; the potential for [212Pb]Pb-PSV-359 to offer strong tumor uptake and clearance from the blood and strong anti-tumor effects; the potential for the application of computational modeling to the customization of chelators to enhance matching of chelators to specific radionuclides; the ability of the Company’s proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides; the opportunity to personalize treatment and optimize patient outcomes using the Company’s complementary imaging diagnostics that incorporate the same targeting peptides; the Company's expectation that its "theranostic" approach enables the ability to see specific tumors and then treat them to potentially improve efficacy and minimize toxicity; the Company’s ability to develop a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations; expectations regarding the potential market opportunities for the Company’s product candidates; the potential functionality, capabilities, and benefits of the Company’s product candidates and the potential application of these product candidates for other disease indications; the Company’s expectations, beliefs, intentions, and strategies regarding the future; the Company’s intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts: Perspective Therapeutics IR Annie Cheng ir@perspectivetherapeutics.com Russo Partners, LLC Nic Johnson / Adanna G. Alexander, Ph.D. PerspectiveIR@russopr.com
